lesinurad and Hepatic-Insufficiency

Clinical development of lesinurad, a selective uric acid reabsorption inhibitor, required analysis of lesinurad in plasma from special patient populations.. EMA and FDA bioanalytical method validation guidance have recommended studying matrix effects on quantitation if samples from special patient populations are to be analyzed. In addition to lesinurad (plasma protein binding 98.2%), the matrix effects from special population plasma on the quantitation of verapamil (PPB 89.6%), allopurinol and oxypurinol (PPB negligible) were also investigated.. The plasma from special population patients had no matrix effects on the three quantification methods with stable isotope labeled internal standard, protein precipitation extraction, and LC-MS/MS detection. The validated lesinurad plasma quantification method was successfully applied for the pharmacokinetic evaluations to support the clinical studies in renal impaired patients.. Special population plasma did not affect quantitation of drugs with a wide range of plasma protein binding levels in human plasma. With the confirmation that there is no impact on quantification from the matrix, the bioanalytical method can be used to support the pharmacokinetic evaluations for clinical studies in special populations.

Topics: Allopurinol; Calibration; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Hepatic Insufficiency; Humans; Kidney; Liver; Oxypurinol; Reference Standards; Renal Insufficiency; Renal Reabsorption; Reproducibility of Results; Tandem Mass Spectrometry; Thioglycolates; Triazoles; Uricosuric Agents; Verapamil